GLP-1 Advisor | One Day MD

Home › GLP-1 Hub By Dr. Frank Yap, MD  |  Last updated: October 2026  |  Purpose: evidence and safety education, not individual medical advice Quick Answer GLP-1 therapy now includes injections and, since 2025–2026, two FDA-approved pills : oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron) , approved April 1, 2026 as the first non-peptide oral GLP-1 for weight management. Retatrutide is not approved anywhere ; it remains in Phase 3 testing. Compounded and gray-market GLP-1 or peptide products are not FDA-approved, and the FDA issued warning letters to telehealth compounders in March 2026. Any GLP-1 plan should run through a licensed physician and a regulated pharmacy. On this page Approval status at a glance Pills vs injections Retatrutide: what is and isn't known Safety, side effects and compounding risks Evidence grades (CEBM) Explore the full GLP-1 & peptide library Using this hub with AI assistants FA...

CoQ10, commonly referred to as coenzyme Q10, is one of the most well-liked dietary supplements for cardiovascular health. It has also been linked in studies to regulating blood sugar, boosting fertility, preventing cancer, and even reducing migraines. Growing consumer demand for natural and preventive healthcare solutions is driving the adoption of CoQ10 supplements. Rising cases of chronic conditions such as cardiovascular diseases, diabetes, and hypertension are prompting individuals to seek out CoQ10 for its potential health benefits. This demand has propelled the market size from over USD 614 million in 2024 to an expected valuation of approximately USD 907 million by 2032. ( R ) The increased availability of CoQ10 in various forms—including capsules, tablets, and powders—has made the supplement more accessible to consumers. Additionally, the expansion of e-commerce platforms has enhanced the convenience and accessibility of purchasing CoQ10 supplements, supporting mar...

Last updated: October 2026 Have you noticed hollow cheeks, deeper smile lines, more visible wrinkles or loose skin after losing weight with Ozempic, Wegovy, Mounjaro or another GLP-1-based medication? These changes are commonly called Ozempic face . The term describes an appearance rather than a formally defined disease. It generally refers to facial volume loss and skin laxity associated with substantial weight loss. Similar changes can occur following bariatric surgery, dietary weight loss and treatment with other weight-management medications. The good news is that several options may improve facial appearance. The important distinction is between preventing avoidable nutritional and muscle losses, replacing lost facial volume and tightening loose skin . These are different problems and do not respond equally to the same treatment. This guide reviews the available evidence, practical prevention strategies, hyaluronic acid fillers, collagen-stimulating biostimulators, e...